SIRTeX SIR-Spheres PMA Supplement Submission Expected By Year-End
This article was originally published in The Gray Sheet
Executive Summary
SIRTeX Medical is looking to follow its March 5 SIR-Spheres PMA approval for localized treatment of unresectable metastatic liver tumors with a PMA supplement submission by the end of the year for a systemic indication
You may also be interested in...
Cephalon Growth Strategy Extends To Devices Via $161 Mil. SIRTeX Purchase
Biopharmaceutical firm Cephalon is expanding its growth strategy to include medical devices with a $161 mil. cash bid to acquire liver cancer technology manufacturer SIRTeX Medical, announced Feb. 12
Cephalon Growth Strategy Extends To Devices Via $161 Mil. SIRTeX Purchase
Biopharmaceutical firm Cephalon is expanding its growth strategy to include medical devices with a $161 mil. cash bid to acquire liver cancer technology manufacturer SIRTeX Medical, announced Feb. 12
Sir-Spheres Selective Radiation Therapy Approvable For Liver Cancer - Panel
Sirtex Medical's Sir-Spheres embolic radiation therapy device for liver cancer is beneficial over traditional chemotherapy - despite the lack of a statistically insignificant increase in patient survival - because it offers a slower time to disease progression, FDA advisory panel members agreed at a Nov. 6 meeting in Rockville, Maryland.